NXL Nexalin Technology, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1527352 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY76.7%
TTM net income YoY-8.0%
TTM EPS YoY108.1%
Revenue 3-yr CAGR29.2%
Net income 3-yr CAGR—
Margins
Gross margin82.4%
Operating margin-3,386.0%
Net margin-3,380.6%
FCF margin—
EBITDA margin—
Returns
ROE-372.6%
ROA-222.9%
ROIC (approx.)-406.6%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets92.0%
Debt / equity0.00x
Current ratio0.69x
Interest coverage-179.02x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-74.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $301,647 | $168,721 | $110,748 | $1.32M | $144,065 |
| Cost of revenue | $61,373 | $36,593 | $25,688 | $363,212 | $21,442 |
| Gross profit | $240,274 | $132,128 | $85,060 | $958,145 | $122,623 |
| R&D expense | $1.08M | $1.19M | $1.92M | $511,000 | $139,000 |
| SG&A expense | $4.40M | $4.23M | $1.90M | $1.49M | $5.22M |
| Operating income | -$8.39M | -$7.75M | -$5.70M | -$1.83M | -$6.02M |
| Interest expense | -$8,240 | -$3,193 | $38,835 | $59,382 | $82,319 |
| Pretax income | -$8.22M | -$7.61M | -$4.65M | — | — |
| Net income | -$8.22M | -$7.61M | -$4.65M | -$1.70M | -$6.08M |
| EBITDA | — | — | -$5.70M | -$1.83M | -$6.02M |
| EPS (basic) | -0.50 | -0.83 | -0.63 | -0.30 | — |
| EPS (diluted) | -0.50 | -0.83 | -0.63 | -0.30 | — |
| Weighted avg. shares (diluted) | 16.39M | 9.22M | 7.36M | 5.57M | — |
| Banking | |||||
| Net interest income | -$8,240 | -$3,193 | $38,835 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $654,783 | $574,485 | $580,230 | $162,743 | $661,778 |
| Short-term investments | $3.07M | $2.91M | $2.37M | $6.83M | — |
| Receivables | $81,571 | $13,043 | $9,369 | $4,875 | $16,303 |
| Inventory | $131,473 | $174,578 | $156,420 | $154,370 | $31,410 |
| Current assets | $4.30M | $3.96M | $3.43M | $7.43M | $752,659 |
| PP&E, net | — | — | — | $503 | $1,039 |
| Intangibles | $336,049 | $260,727 | $105,528 | — | — |
| Total assets | $4.64M | $4.22M | $3.63M | $7.43M | $753,698 |
| Current liabilities | $887,333 | $546,694 | $425,281 | $1.95M | $2.36M |
| Total liabilities | $887,333 | $546,694 | $425,281 | $1.95M | $2.44M |
| Shareholders' equity | $3.75M | $3.68M | $3.21M | $5.48M | -$1.68M |
| Shares outstanding | 639,544 | 13.30M | 7.44M | 7.29M | 4.88M |
| Cash flow statement | |||||
| Operating cash flow | -$4.96M | -$3.94M | -$3.84M | -$2.22M | -$1.08M |
| Investing cash flow | -$131,991 | -$577,539 | $4.45M | -$6.79M | — |
| Financing cash flow | $5.17M | $4.52M | -$200,000 | $8.51M | $1.66M |
| Depreciation & amortization | — | — | $503 | $535 | $537 |
| Stock-based compensation | $3.12M | $3.56M | $2.41M | $270,670 | $4.48M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.